

OLARTEMOURE

OLARTE MOURE & ASOCIADOS LTDA.

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES

E. _____ S. _____ D. _____

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 06-106466- -00009-0000

Fecha: 2012-04-25 16:52:39 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 13

Re: Expediente No. 06-106.466

Solicitud de patente de invención titulada: “COMPOSICIONES DE DALBAVANCINA PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS”

Solicitante: VICURON PHARMACEUTICALS, INC

Nuestra Ref.: P2006/0000209

RESPUESTA AL OFICIO No.19444 NOTIFICADO POR FIJACION EN LISTA No. 475

DE FECHA 15 DE DICIEMBRE DE 2011

(SEGUNDO EXAMEN DE FONDO)

CARLOS R. OLARTE, mayor de edad y vecino de Bogotá, identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad solicitante, me permito manifestar lo siguiente ante el auto emanado por ese Despacho, dentro del plazo legal de prórroga previsto en el artículo 45 de la Decisión 486, en los siguientes términos:

1. En primer lugar, con el ánimo de brindar mayor claridad a la presente solicitud, me permito adjuntar un **Capítulo Reivindicatorio Modificado**, que reemplaza en su totalidad al Capítulo Reivindicatorio Modificado presentado adjunto a mi respuesta al primer examen de fondo de fecha 04 de mayo de 2011.

Así entonces, el Capítulo Reivindicatorio Modificado contiene los siguientes cambios:

- se han eliminado las Reivindicaciones 2 a 122;
- se ha eliminado el término “aproximadamente” de todas las reivindicaciones.
- las nuevas Reivindicaciones 1 y 2 corresponden a una limitación de la antigua Reivindicación 1 al especificar la naturaleza del estabilizante, y su proporción, así como la proporción dalbavancina:estabilizante, en donde dicha composición se

OLARTEMOURE

OLARTE MOURE & ASOCIADOS LTDA.

degrada no más de 6% y no contiene más del 6% de MAG en condiciones especificadas.

Valga anotar que las modificaciones efectuadas al Capítulo Reivindicatorio cumplen a cabalidad con lo estipulado en el Artículo 34 de la Decisión 486, ya que éstas de ninguna manera implican una ampliación de la protección correspondiente a la divulgación contenida en la solicitud inicial. Por el contrario, éstas corresponden a una franca limitación de la materia reivindicada.

2. a- El Examinador argumenta que el Capítulo Reivindicatorio de la presente solicitud no es claro ni conciso por las siguientes razones:

- las reivindicaciones no incluyen las características esenciales de la invención, a saber: composiciones que contienen dalbavancina y un agente estabilizante, estable a diferentes temperaturas (refrigerada y ambiente) con menores productos de degradación;
- las composiciones reivindicadas no pueden ser caracterizadas mediante componentes intrínsecos del ingrediente activo (factores de dalbavancina), cuya presencia depende de las condiciones de fermentación. La composición reivindicada debe ser definida en términos de sus ingredientes (por ejemplo como se describe en la Tabla 7);
- "distribución de HPLC" no es un parámetro habitual en el campo farmacéutico para caracterizar las cantidades de ingredientes en las composiciones. Por el contrario, los parámetros de HPLC se utilizan comúnmente como factores de separación y purificación, que a su vez, corresponden a un resultado a alcanzar.
- el Capítulo Descriptivo describe porcentajes y pesos de dalbavancina, los cuales son parámetros aceptables a ser incluidos en las reivindicaciones;
- el preámbulo de las Reivindicaciones 1, 19, 36 y 53 utiliza la expresiones "forma de dosificación" y "composiciones farmacéuticas", las cuales son equivalentes, por lo que se repite la materia reclamada;
- las reivindicaciones contienen términos relativos, tales como "no más de", "al menos", "no menos de", los cuales no permiten especificar el alcance de la materia reivindicada;
- las Reivindicaciones 114 a 120 caracterizan un proceso de secado a través de un resultado a alcanzar (MAG), que no define específicamente el procedimiento reivindicado. Los procesos deben ser definidos a través de secuencias de pasos y condiciones realizadas;

OLARTEMOURE

OLARTE MOURE & ASOCIADOS LTDA.

- el proceso de las Reivindicaciones 98 a 120 incluye innumerables combinaciones de condiciones y pasos. El Examinador sugiere limitar los procesos reclamados usando rangos específicos;
- las reivindicaciones no son claras, ya que contienen un número excesivo de reivindicaciones.

Adicionalmente, el Examinador señala que las reivindicaciones reclaman factores individuales de dalbavancina, los cuales no están debidamente soportados en el Capítulo Descriptivo. No hay ejemplos que enseñen las composiciones con únicamente un factor de dalbavancina, por el contrario, las composiciones del Capítulo Descriptivo contienen todos los factores dalbavancina. El Capítulo Descriptivo no muestra que cada factor dalbavancina haya sido purificado y aislado.

b- En primer lugar, llamo respetuosamente la atención del Examinador sobre las limitaciones introducidas en el Capítulo Reivindicatorio Modificado adjunto, en el que se reclama en la Reivindicación 1 una composición farmacéutica que comprende dalbavancina y un estabilizante que comprende manitol y lactosa en proporción 1:1, siendo la proporción dalbavancina:manitol:lactosa de 4:1:1, en donde la composición tiene un pH de 3 a 5 y en donde la composición se degrada no más de 6% a 40° C después de 3 a 6 meses, y en la Reivindicación 2 una composición farmacéutica que comprende dalbavancina, un estabilizante que comprende manitol y lactosa en proporción 1:1, siendo la proporción dalbavancina:manitol:lactosa de 4:1:1, en donde la composición tiene un pH de 3 a 5 y en donde la composición contiene no más de 6% de MAG a 40° C después de 3 a 6 meses.

Teniendo en cuenta lo anterior, particularmente que la presente invención ahora reclama una composición que sólo contiene dalbavancina, y en la que no sólo se especifica la naturaleza de los estabilizantes, sino su proporción interna y respecto al principio activo, así como el pH, considero superadas las objeciones hechas por el Examinador, ya que la materia ahora reclamada es clara, concisa y se encuentra sustentada en su totalidad por el Capítulo Descriptivo.

3. a- El Examinador señala que la patente US5750509 (D1) afecta la novedad de las Reivindicaciones 2, 5 a 20, 23 a 37, 40 a 54, 57 a 69, 121 y 122, y la patente EP0438747 (D2) afecta el nivel inventivo de las Reivindicaciones 3, 4, 21, 22, 38, 369, 55 y 56.

El Examinador argumenta que D1, describe composiciones estériles en polvo que comprenden 40mg/kg de dalbavancina (columna 28, líneas 25-29), las cuales también contienen agentes estabilizantes y dispersantes (columna 28, líneas 13-15). Adicionalmente, D1 menciona que la

OLARTEMOURE

OLARTE MOURE & ASOCIADOS LTDA.

dalbavancina es un complejo de glicopéptidos, que comprende dalbavancina B₀ (columna 2, líneas 45-50) y sus isómeros, y al menos un factor de dalbavancina adicional seleccionado entre A₀, A₁, B₁, C₁ y C₀. por lo que las Reivindicaciones 2, 5 a 20, 23 a 37, 40 a 54, 57 a 69, 121 y 122 carecen de novedad.

En cuanto al nivel inventivo, el Examinador argumenta que D2 describe composiciones estables de antibióticos glicopéptidos (cloroorienticina B y vancomicina) en polvo liofilizado inyectable, que comprenden uno o más sacáridos como agentes estabilizantes (glucosa, fructosa, lactosa, maltosa, manitol, sorbitol o dextrano), las cuales reducen la formación de productos de degradación. El Examinador concluye que de acuerdo con D2, utilizar sacáridos como agentes estabilizantes en composiciones de dalbavancina (tal como se reclaman en D1) no reviste nivel inventivo alguno.

Por último, y teniendo en cuenta el arte previo, particularmente D1, el Examinador señala que la presente invención carece de unidad de invención. El Examinador argumenta que las reivindicaciones reclaman los siguientes objetos no relacionados:

- i) Reivindicaciones 1 a 69 y 98 a 120: formas de dosificación en polvo que comprenden los factores dalbavancina B₀ e isoB₀, y al menos un factor adicional (A₀, A₁, B₁, B₂, C₀, C₁), y el proceso para el secado de dalbavancina;
- ii) Reivindicaciones 70 a 97: análogos dalbavancina de Fórmulas I, 1 y 2.

b- i) En primer lugar, llamo nuevamente la atención del Examinador sobre las limitaciones introducidas en el Capítulo Reivindicatorio Modificado adjunto, tal y como se explicaron anteriormente en el punto 2.b. La presente invención ahora reclama una composición que sólo contiene dalbavancina, y en la que no sólo se especifica la naturaleza de los estabilizantes, sino su proporción interna y respecto al principio activo, así como el pH de la misma.

Teniendo en cuenta lo anterior y el arte previo citado por el Examinador, me permito señalar que ni D1 ni D2 describen composiciones que comprenden dalbavancina, manitol y lactosa en proporción 4:1:1, con las características de degradación reclamadas en las nuevas reivindicaciones, es decir, donde el activo es exclusivamente dalbavancina, el estabilizante comprende específicamente manitol y lactosa, y tiene un pH de 3 a 5, donde adicionalmente, la composición contiene no más de 6% de MAG a 40° C después de 3 a 6 meses.

En este punto, vale la pena recordar para fundamentar una afectación válida contra la novedad de una invención, el arte previo debe divulgar explícitamente todas y cada una de las características de la invención.¹ Es más, el Tribunal Andino de Justicia ha determinado que para establecer una objeción de novedad válida, la divulgación del arte previo debe ser lo suficientemente completa para que una persona versada en la materia pueda usar dicha información para reproducir y explotar la invención.² En el presente caso, es claro que nada en D1 o D2 afecta la novedad de la presente solicitud, pues de ninguna manera revela las composiciones, con las características particularmente reclamadas.

ii) En cuanto al nivel inventivo, me permito señalar que la presente invención contiene un estabilizante compuesto por manitol y lactosa en proporción 1:1, que junto a la dalbavancina se encuentran en proporción 4:1:1. Dicha sustancia estabilizante, compuesta por manitol y lactosa, resultó ser sorprendentemente ventajosa sobre las composiciones que no contienen una sustancia estabilizante, tal y como se demuestra a continuación:

Compuesto	Manitol (mg/vial) ¹	Lactosa (mg/vial) ¹	pH ¹	40°C		25°C		5°C	
				ΔB ₀ (6 mos) ²	ΔMAG (6 mos) ³	ΔB ₀ (12 mos) ⁴	ΔMAG (12 mos) ⁵	ΔB ₀	ΔMAG
A	62,5		3,4	5,3	5,1	1,5	1,1		
B			3,69	14,1	15,3	6,1	6,8		
C	62,5		3,8	6,7	7,3	2,3	2,2		
D			3,01	17,4	19,2	7,9	8,6		
E	62,5		3,01	8,4	8,7	3,1	3,1		
F			4,5	10,9	12,1	5,1	5,4		
G	62,5		4,5	4,6	4,8	1,9	1,6		
H	62,5		5,3	2,3	3,4	0,7	1,1		
I	125		5	2,1	2,9	0,3	0,5		
J	62,5		5	3,2	3,9	1,2	1,2		
K	125		4,5	2,3	3,3	0,1	0,5		
L	62,5		4,5	3,6	5,0	1,0	1,5		
M	62,5	62,5	4,5	1,2	2,2	0,6	0,6		
N		125	4,5	1,8	3,0	0,6	1,2		
O	125		3,3	4,0	5,2	0,5	1,0		
Sustancia fármaco (Tabla 3.2.S.7.3-5) ⁶			2.4-2.7					5.8 (36 mos)	5.4 (36 mos)
Sustancia fármaco (Tabla 3.2.S.7.3-4) ⁷			2.5-2.6			9.2 (6 mos)	8.9 (6 mos)		

¹ - ver Capítulo Descriptivo, tabla 7, página 91

² - ver tablas en Fig. 2A y 4A del Capítulo Descriptivo

³ - ver tablas en Fig. 2B y 4B del Capítulo Descriptivo

¹ Manual Andino de Patentes. OMPI, EPO, Secretaría de la Comunidad Andina, 2004. Sección 9.4.

² Proceso 06-IP-89 (<http://intranet.comunidadandina.org/Documentos/Procesos/209-IP-2005.doc>);
y Proceso 36-IP-2004 (<http://www.notinet.com.co/serverfiles/servicios/archivos/30jul04/ca36-04.htm>)

OLARTEMoure

OLARTE MOURE & ASOCIADOS LTDA.

⁴ - ver tablas en Fig. 1A y 3A del Capítulo Descriptivo

⁵ - ver tablas en Fig. 1B y 3B del Capítulo Descriptivo

⁶ - ver Anexo 1

⁷ - ver Anexo 1

La tabla anterior resume los datos de estabilidad que se encuentran en las Figuras 1 a 4 del Capítulo Descriptivo, que muestran datos para diversas formulaciones que no contienen una sustancia estabilizadora, manitol, lactosa, o manitol y lactosa, a valores diferentes de pH. Como se puede evidencia de lo anterior, las composiciones que **no contienen** sustancias estabilizadoras (por ejemplo, composiciones B, D y F) presentaron mayor degradación que las composiciones que contienen manitol, lactosa, o una combinación de manitol y lactosa. En particular, la Composición M, que contiene manitol y lactosa en proporción 1:1, presentó los valores de degradación más pequeños.

Adicionalmente, es importante señalar que de manera sorprendente e inesperada, la dalbavancina fue más estable en presencia de lactosa. Una persona medianamente versada en la materia habría podido pensar que la lactosa podría inestabilizar la dalbavancina, al ser la lactosa un azúcar reductor, esperando que reaccionara con la amina secundaria de la dalbavancina y generara una reacción de Maillard (ver Anexo 1 adjunto - Wirth et al³). De forma inesperada, dicha reacción no ocurrió, y por el contrario, cuando la dalbavancina se formuló con manitol y lactosa se favoreció la estabilidad de la dalbavancina.

Lo anterior, cobra importancia particularmente porque la evaluación del nivel inventivo debe centrarse únicamente en la cuestión de si, para la persona medianamente versada en la materia, la materia reivindicada habría podido derivarse de manera obvia a partir del arte previo y sin necesidad de investigación adicional alguna. En el presente caso, es claro que la persona medianamente versada en la materia, siguiendo las enseñanzas de D1 o D2, habría estado necesariamente inclinada a producir composiciones farmacéuticas diferentes a las aquí reivindicadas. Nada en D1 o D2 habría sugerido a la persona medianamente versada en la materia obtener una composición farmacéutica que comprende dalbavancina, un estabilizante que comprende manitol y lactosa, en proporción 4:1:1, y tiene un pH de 3 a 5, donde la composición contiene no más de 6% de MAG a 40° C después de 3 a 6 meses.

Lo anterior evidencia que el Examinador anticipa indebidamente conclusiones, que sin basarse en enseñanzas y motivaciones del arte previo, conducirían a la invención, como si de armar un rompecabezas se tratara. La única forma en que el Examinador podría haber llegado a todas estas conclusiones durante el análisis de patentabilidad sería al aplicar un análisis en retrospectiva

³ Wirth, D., et al. "Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine". Contribución entre Laboratorios Lilly, Eli Lilly y Compañía, Lafayette, Indiana 47905, Octubre 23, 1997. pp. 31 a 39.

OLARTEMOURE

OLARTE MOURE & ASOCIADOS LTDA.

luego de analizar la presente invención. Este tipo de análisis es conocido en la doctrina y jurisprudencia internacional como análisis en retrospectiva o “hindsight”, el cual se proscribe incluso por el Manual Andino de Patentes (MAP), conforme al cual “...la búsqueda de anterioridades se efectúa a posteriori, tomando como punto de partida la misma invención,...el examinador debe realizar el esfuerzo intelectual de colocarse en la situación que ha tenido que afrontar el técnico con conocimientos medios en la materia en un momento en que la invención no era conocida, es decir antes de la invención”⁴ (mi subrayado). No es apropiado anticiparse a los resultados presentados por la invención, ya que así, siempre resultará "obvio" todo objeto de una solicitud de patente, pues inevitablemente está parecerá derivada de la teoría en que se basa su desarrollo, sin dar mayor importancia al trabajo, incertidumbre, intelecto y creatividad involucrados en la invención para llegar a la solución del problema planteado en la solicitud.

A la luz del arte previo y sus enseñanzas, no cabe duda que la composición aquí reivindicada reviste novedad y nivel inventivo.

3. Por todo lo anterior, considero que las objeciones presentadas por el Examinador en su segundo examen de fondo han sido resueltas y por consiguiente solicito respetuosamente que se tengan por cumplidos los requisitos de patentabilidad, y se proceda con la concesión de la patente.

Atentamente,



CARLOS R. OLARTE
C.C. No. 79.782.747 de Bogotá
T.P. 74.295

Anexos:

- Capítulo Reivindicatorio Modificado.
- Anexo 1: Wirth et al. “Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine”. Contribución entre Laboratorios Lilly, Eli Lilly y Compañía, Lafayette, Indiana 47905, Octubre 23, 1997. pp. 31 a 39.

⁴ Manual Andino de Patentes. (2004). Sección 10.2. (disponible en <http://www.comunidadandina.org/public/patentes.pdf>).

CAPITULO REIVINDICATORIO MODIFICADO

(Segundo Examen de Fondo)

1. Una composición farmacéutica que comprende dalbavancina y un estabilizante que comprende manitol y lactosa en proporción 1:1, siendo la proporción dalbavacina:manitol:lactosa de 4:1:1, en donde la composición tiene un pH de 3 a 5 y en donde la composición se degrada no más de 6% a 40°C después de 3 a 6 meses.
2. Una composición farmacéutica que comprende dalbavancina, un estabilizante que comprende manitol y lactosa en proporción 1:1, siendo la proporción dalbavacina:manitol:lactosa de 4:1:1, en donde la composición tiene un pH de 3 a 5 y en donde la composición contiene no más de 6% de MAG a 40°C después de 3 a 6 meses.

Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine

DAVID D. WIRTH*, STEVEN W. BAERTSCHI, ROSS A. JOHNSON, STEVEN R. MAPLE, MARYBETH S. MILLER, DIANA K. HALLENBECK, AND STEPHEN M. GREGG

Contribution from the Lilly Research Laboratories, Eli Lilly and Company, Lafayette, Indiana 47905

Received May 21, 1997. Final revised manuscript received October 20, 1997. Accepted for publication October 23, 1997[®].

Abstract □ Analysis of commercially available generic formulations of fluoxetine HCl revealed the presence of lactose as the most common excipient. We show that such formulations are inherently less stable than formulations with starch as the diluent due to the Maillard reaction between the drug, a secondary amine hydrochloride, and lactose. The Amadori rearrangement product was isolated and characterized; the characterization was aided by reduction with sodium borohydride and subsequent characterization of this reduced adduct. The lactose–fluoxetine HCl reaction was examined in aqueous ethanol and in the solid state, in which factors such as water content, lubricant concentration, and temperature were found to influence the degradation. *N*-Formylfluoxetine was identified as a major product of this Maillard reaction and it is proposed that *N*-formyl compounds be used as markers for this drug–excipient interaction since they are easy to prepare synthetically. Many characteristic volatile products of the Maillard reaction have been identified by GC/MS, including furaldehyde, maltol, and 2,3-dihydro-3,5-dihydroxy-6-methyl-4*H*-pyran-4-one. Close similarity between the degradation products of simple mixtures and formulated generic products was found; however, at least one product decomposed at a rate nearly 10 times that predicted from the simple models. Maillard products have also been identified in unstressed capsules. The main conclusion is that drugs which are secondary amines (not just primary amines as sometimes reported) undergo the Maillard reaction with lactose under pharmaceutically relevant conditions. This finding should be considered during the selection of excipients and stability protocols for drugs which are secondary amines or their salts, just as it currently is for primary amines.

Introduction


The Maillard reaction is named after Louis Maillard, who reported over 80 years ago that some amines and reducing carbohydrates react to produce brown pigments.¹ It has been extensively studied and reviewed, especially in the food and nutrition literature.² More recent reviews cover not only the chemistry of foods but human physiology as well.³ The first product of this reaction is a simple glycosylamine,⁴ which readily undergoes the Amadori rearrangement to produce 1-amino-1-deoxy-2-ketoses.⁵ The large body of literature on these reactions is due to the multitude of possible reaction pathways and products, including fragmentations of the carbohydrates and formation of aromatic compounds from cyclization/dehydration processes.⁶ Reducing disaccharides also undergo this reaction,⁷ and it is a well-documented process for the degradation of lactose during the heating of milk.⁸ Reducing carbohydrates such as glucose, maltose, and lactose are substrates for the Maillard reaction since their cyclic

tautomers are in equilibrium with their more reactive aldehyde forms; nonreducing carbohydrates such as mannitol, sucrose, and trehalose are not subject to Maillard reactions. Although early scientists believed that only primary aromatic amines were capable of this reaction, subsequent research has shown that nearly all primary and secondary amines, aromatic or aliphatic, are capable of this reaction.⁹ Amino acids and proteins are also substrates for the Maillard reaction.¹⁰ The impact of these reactions on the stability of pharmaceuticals has also been known for some time and was recently reviewed.¹¹

Prozac, the world's largest selling antidepressant, is a selective serotonin reuptake inhibitor;¹² it has been used by over 25 million people in more than 90 countries. Its active ingredient is fluoxetine hydrochloride, **1**, and the diluent is starch. Within the past few years, many generic formulations containing fluoxetine HCl have been manufactured and sold in countries lacking patent protection or in which the patents have expired. We have recently examined several dozen of these products and find that a majority of them contain lactose as their primary diluent. Lactose is widely used as a diluent for capsules and tablets due to its low price, high purity, and excellent compression and stability characteristics. Although its ability to undergo nonenzymatic browning (Maillard) reactions has long been known to formulation scientists, some reports have suggested this interaction to be largely restricted to primary amines.¹³ The origin of this view is likely founded in early literature reports of the slower browning of glucose mixtures of *N*-methyl glycine as compared to glycine itself¹⁴ and work on the browning of mixtures of lactose and methylated amphetamines,¹⁵ studies which measured optical density only, not characteristic Maillard products. Although these reports showed faster rates of browning of mixtures of reducing carbohydrates with primary amines as compared to secondary ones, they do not support the conclusion that secondary amines should generally be incapable of the Maillard reaction.

The generally accepted mechanism of glycosylation and the Amadori rearrangement are summarized in Scheme 1 for a secondary amine.¹⁶ The imminium ion intermediate can be formed from either primary or secondary amines (but not tertiary ones) and is the key intermediate in both closure to the glycosylamine and deprotonation to the enol version of the Amadori rearrangement product, ARP. The multitude of individual steps in this mechanism allows for considerable variation in the kinetics. For example, the hydrolysis of the glycosylamine of benzylamine and glucose is faster at pH 5 than hydrolysis of the corresponding glycosylamine with piperidine, but the reverse order of reactivity is observed at pH 9.¹⁷ Kinetic studies of the Maillard reaction have been reviewed and will not be explored in depth in this paper.¹⁸ In view of the well-

[®] Abstract published in *Advance ACS Abstracts*, December 15, 1997.



Scheme 1—Mechanism of glycosylation and Amadori rearrangement with secondary amines.

known interaction of reducing carbohydrates and secondary amines, as reported in the carbohydrate and food science literature,¹⁹ we have investigated the Maillard/Amadori reactions of the lactose–fluoxetine system and report our findings here. Detailed mechanistic work such as identification of the rate-determining step and full kinetic analysis as a function of the amine, carbohydrate, and reaction conditions are left for future studies.

Experimental Section

Materials—Fluoxetine HCl and Prozac were obtained from Eli Lilly and Co. generics A, N, O, and Z were obtained in pharmacies outside the United States and were unexpired formulated 20 mg products. Lactose monohydrate was obtained from Aldrich Chemical Co, Milwaukee, WI, and spray-dried lactose was from Foremost Ingredients Group, Baraboo, WI. The anhydrous lactose forms were obtained from Sheffield Products, Norwich, NY. The acetonitrile was spectroscopic grade, obtained from EM Science, Gibbstown, NJ. Reagent grade trifluoroacetic acid was obtained from Aldrich Chemical Co. and was distilled prior to use. Other chemicals and the authentic samples of compounds listed in Table 6 were purchased from Aldrich Chemical Co. and were used as received. Ethanol was anhydrous and denatured with 5% methanol.

NMR—Nuclear magnetic resonance (NMR) spectroscopy for compounds **1**, **2**, **3**, and **6** was carried out on a Bruker AC300 spectrometer with ^1H and ^{13}C operating frequencies of 300.13 and 75.46 MHz, respectively. Additional experiments on compound **6** were carried out on a Bruker AMX500 with ^1H and ^{13}C operating frequencies of 500.14 and 125.77 MHz, respectively.

GC/MS—Gas chromatography/mass spectrometry was performed on a MicroMass TRIO II quadrupole mass spectrometer controlled using the Masslynx operating system. The instrument was equipped with a Hewlett-Packard Model 5890 gas chromatograph which was fitted with a Scientific Instruments Services short path thermal desorption Model TD 4 system and CryoTrap unit. The mass spectrometer was operated in the EI+ mode and calibrated daily against FC-43. Mass spectral data were obtained in the centroid mode by scanning the mass range from 33 to 600 amu at a rate of 1260 amu/s and using an interscan time delay of 0.05 s.

For the analysis of products from solid-state samples, the contents of one 20 mg capsule of fluoxetine HCl product or mixtures of 20 mg of bulk fluoxetine HCl and 200 mg of lactose were added to a 10 mL glass vial which was crimp sealed with a

Teflon-lined rubber septum. The vials were heated at 100 °C for 20 h. A stainless steel GLT short path thermal desorption tube packed with 100 mg of Tenax-TA which had been preconditioned with helium purge at 250 °C and fitted with a needle was inserted into the vial. A second needle connected to a helium source was inserted into the vial and the flow rate set at approximately 7 mL/min. The vial headspace gases were purged onto the Tenax TA tube for either 5 or 60 min. The GLT tube was then transferred to the short path thermal desorption unit for desorption onto the gas chromatographic column. The following conditions were used for the transfer and chromatographic analysis. Sample transfer: gas purge time, 0.5 min; desorption time, 5 min; GLT desorption temperature, 100 °C initial then 40 °C/min to 200 °C; column cryotrap at –100 °C. GC conditions: injector, 150 °C; transfer line to mass spectrometer, 300 °C; split flow, 7 mL/min or 50 mL/min; the cryotrap was heated rapidly to 250 °C to desorb material onto the GC column; oven temperature program, 40 °C for 3 min then 10 °C/min to 300 °C and hold 3 min; chromatographic column, DB-1, 30 m $\times$ 0.25 mm i.d. and 1.0 mm film.

HPLC—High performance liquid chromatography was performed with a Spectra Physics SP8700XR pump, a Spectroflow 757 detector (Anspec) set at 260 nm, a ChromJet integrator by Spectra Physics, and an Alcott 728 autosampler incorporating a Valco injection valve with a 10 μL fixed loop. The column was a Zorbax RX-C8, 25 cm by 4.6 mm, 5 μm particles (Mac-Mod Analytical, Inc., Chadds Ford, PA) maintained at ambient temperature. The flow rate was 1.00 mL/min throughout. The two eluting solutions used were A = 0.07% trifluoroacetic acid (TFA) in water, v/v; B = 0.07% TFA in acetonitrile. The elution program started at 80:20 A:B for 5 min, ramped linearly to 15:85 A:B at 30 min, held there until 35 min, and returned to 80:20 A:B at 40 min. Injections were made no sooner than every 50 min. The approximate elution times are **1** at 21 min, **2** at 18.4 min, **3** at 27 min, and **4** at 17.9 min. For MS detection, samples were analyzed on MicroMass (formerly Fisons) Quattro II and Platform II LC/MS systems in the positive ion electrospray mode, scanning from 100 to 1000 amu, generating centroid data. Further details and example chromatograms have been published elsewhere.²⁰ This method allows for the detection and quantitation of impurities which span a wide range of polarities, including nonpolar compounds which are not eluted using the isocratic US Pharmacopeia method.²¹

Lactose–Fluoxetine Amadori Rearrangement Product (ARP, 2)—In a 500 mL round-bottom flask equipped with an overhead stirrer, thermometer, and condenser were combined 20 g of α -D-lactose monohydrate (55.5 mmol), 10 g of fluoxetine HCl (28.9 mmol), 250 mL of ethanol, 120 mL of dimethylacetamide, and 4 mL of triethylamine (28.7 mmol). The nearly homogeneous mixture was stirred at reflux for 24 h. The reaction mixture was filtered at ambient temperature and the wetcake was washed with 50 mL of ethanol. The filtrate was evaporated in vacuo to a thick brown solution (112 g), to which were added 300 mL of ethyl acetate, 300 mL of 20% aqueous sodium chloride, and 30 mL of ether. The pH was adjusted to 11 with 50% sodium hydroxide. White solids which formed during the pH adjustment were filtered and the layers were separated. The bottom layer was discarded and the upper layer was set aside. To the milky middle layer were added 300 mL of ethyl acetate and 30 mL of ether. The layers were separated and the combined organic layers were evaporated in vacuo to a thick brown oil (42.8 g), to which were added 175 mL of 20% aqueous sodium chloride, 400 mL water, and 550 mL chloroform. The pH was adjusted to 1.5 with concentrated HCl. The layers were separated and to the aqueous layer were added 60 g of NaCl, 500 mL of ethyl acetate, and 50 mL of ether. The pH was adjusted to 10.6 with 50% NaOH, and the layers were separated. The ethyl acetate layer was evaporated in vacuo to a residue (4.7 g) which was 85% pure by HPLC analysis at 260 nm. Standard ^1H and ^{13}C NMR spectra were acquired on a sample of **2** prepared by dissolving 50–60 mg of the material in DMSO- d_6 . A partial list of assignments has been made based on comparison to fluoxetine and is shown in Table 1. Flow-injection mass spectrometry indicated the molecular weight to be 633 ($\text{M} + \text{H}^+$, m/z 634). Accurate mass FAB-MS measurements of the protonated molecular ion ($\text{M} + \text{H}^+$) indicated the elemental composition to be $\text{C}_{29}\text{H}_{39}\text{NO}_{11}\text{F}_3$ (calcd 634.2475, measured 634.2487).


Reduced Adduct (6)—In a 50 mL round-bottom flask equipped with an overhead stirrer, a thermometer, and a condenser were combined 1.5 g of ARP, **2** (2.37 mmol), 15 mL of ethanol, and 1.79

g of NaBH_4 (47.4 mmol, 20 equiv). The mixture was stirred at reflux for 1 h and at 70 °C for 1 h. The mixture was cooled to ambient temperature and 10 mL of ethanol was added. Excess NaBH_4 was quenched by the dropwise addition of 5 mL of acetone at 5 °C. The mixture was evaporated to a wet residue under vacuum at 35 °C. To the residue were added 200 mL of 20% aqueous sodium chloride and 200 mL of CHCl_3 , and the pH was adjusted to 2.2 with concentrated HCl. The layers were separated (after settling overnight). To the CHCl_3 layer were added 100 mL of CHCl_3 and 200 mL of water, and the pH was adjusted to 2.2 with concentrated HCl. The layers were separated, to the water layer were added 300 mL of ethyl acetate and 30 mL of ether, and the pH was adjusted to 10.6 with 50% NaOH. The layers were separated, and the ethyl acetate layer was concentrated under vacuum, producing 0.4 g of residue which contained 80% of the desired reduced fluoxetine-lactose adduct, **6**, by HPLC analysis at 260 nm. Extensive NMR experiments to confirm the structure of **6** were carried out on a sample prepared by dissolving ~60 mg in $\text{DMSO}-d_6$. The experiments performed were ^{13}C DEPT (distortionless enhancement by polarization transfer), 2D ^1H - ^1H COSY (correlation spectroscopy),²² 2D ^1H - ^{13}C HMQC (heteronuclear multiple quantum coherence),²³ and 2D ^1H - ^{13}C HMBC (heteronuclear multiple bond correlation).²⁴ The NMR assignments are shown in Table 1. Mass spectrometry (infusion, electrospray) verified the molecular weight by the presence of a large $\text{M} + 1$ ion at 636 amu.

N-Formylfluoxetine (3)—Acetic formic anhydride was prepared by stirring acetic anhydride (4.87 mL, 51.6 mmol) and formic acid (7.78 mL, 206 mmol) in a beaker for 5 min. Fluoxetine HCl (4.5 g, 12.9 mmol) and methylene chloride (30 mL) were placed in a 100 mL round-bottomed flask. Sodium hydroxide (1 M, 30 mL, 30 mmol) was added. The solution was stirred at room temperature for 5–10 min. The layers were separated, and the organic layer was dried with sodium sulfate and filtered. The filtrate was placed in a 100 mL round-bottomed flask, and the acetic formic anhydride was added. The reaction was stirred at room temperature for 5 h and extracted with a 10% sodium bicarbonate solution (3 × 50 mL). The organic layer was dried with sodium sulfate and filtered. The filtrate was concentrated to an oil (1.5 g) which solidified upon standing (mp 65–67 °C). The purity by the gradient HPLC method was 98.9%. The major and minor rotomers about the amide bond are identified in the following NMR spectra. ^1H NMR (300 MHz, CD_2Cl_2) 8.03–7.96 (dd, 1 H), 7.52–7.43 (d, 2H), 7.41–7.23 (m, 5H), 6.98–6.88 (dd, 2H), 5.30–5.22 (m, 1H, minor), 5.22–5.16 (m, 1H, major), 3.62–3.48 (m, 2H, major), 3.44–3.16 (m, 2H, minor), 2.94 (s, 3H, minor), 2.88 (s, 3H, major), 2.32–1.96 (m, 2H); ^{13}C NMR (CD_2Cl_2 , major rotomer) 162.79, 160.56, 140.55, 129.28, 128.51, 127.15, 126.14, 122.99, 116.16, 77.44, 46.22, 37.23, 29.56; (minor rotomer) 162.75, 160.84, 141.01, 129.15, 128.34, 127.05, 126.24, 123.42, 116.25, 78.51, 41.52, 36.11, 34.89; ^{19}F NMR (282 MHz, CD_2Cl_2) –62.14, –62.2; IR (KBr) 2934, 2875, 1689, 1334, 1249, 1117, 847 cm^{-1} ; MS (CI^+) *m/z* 338 (25), 176 (100), 143 (43).

Reactions in Aqueous Ethanol—Fluoxetine HCl (0.50 g, 1.45 mmol) and lactose monohydrate (5.0 g, 13.9 mmol) were combined with 5.0 mL of ethanol and 7.5 mL of water in each of four separate flasks. The mixtures were heated to 60 °C and vigorously stirred with a mechanical agitator. Potassium hydroxide (85% assay, amounts of 0, 7, 47, or 100 mg) was added, and the reactions were monitored by the above HPLC method. The equivalents of KOH based on the fluoxetine and the results are given in Table 2. The apparent pH (called pH^*) was measured by direct insertion of a calibrated glass electrode into the warm reaction mixture. Samples were diluted 1:5 with eluent for HPLC measurement. The fluoxetine concentration was measured versus an external standard and the mole percent concentrations of **2** and **3** were taken as equal to their area percent values since their molar response factors were measured on authentic material and found to be within 5% of that of fluoxetine itself.

Solid-State Screening Studies—For the screening studies, 5.0 g of lactose and 0.50 g of fluoxetine HCl were combined and mixed one of three ways, described here according to their designation in Table 3. Those tumbled were placed in capped glass bottles and strapped to a horizontal rotating rod for 40 min. Those that were ground were mixed thoroughly in a standard glass mortar and pestle for several minutes. To those labeled "wet grind" was added 0.5 g water before the mortar and pestle grinding operation. Some experiments, identified with a Y in the column



Scheme 2—Maillard reaction of lactose and fluoxetine HCl.

headed Mg stearate, were repeated with 0.04 g of magnesium stearate added before the blending or grinding operation. Four commonly available types of lactose were screened: crystalline monohydrate; a mixture of crystalline and spray-dried monohydrate; and two particle size grades of anhydrous lactose, granular and finely milled. After mixing, the samples were heated in an oven at 98 °C for 24 h in glass vials with loose-fitting plastic caps. The samples were analyzed with the gradient HPLC method and the results are reported using fluoxetine as the standard. Since compounds **2** and **3** have the same molar response as fluoxetine, the levels given for these impurities are molar yields. The total impurity level is estimated by assuming that the molar responses of all impurities are equal to fluoxetine's and thus can be compared on a relative basis only.

Solid-State Kinetic Studies—Lactose (5.0 g, in separate experiments, the monohydrate, anhydrous lactose, and monohydrate containing an additional 0.10 g of magnesium stearate) and fluoxetine HCl (0.50 g) were mixed thoroughly with a mortar and pestle and 1.8 g of the mixtures was added to each of three 10 mL glass vials. The vials were lightly capped and placed in equilibrated ovens at 75, 85, or 95 °C. Samples of the solids were removed at 23, 47, 95, 175, and 287 h for the 75 °C experiment; at 6, 23, 47, 99, and 122 h for the 85 °C experiment; and at 2, 6, 13, 21, and 28 h for the 95 °C experiment. The samples were assayed as described for the screening studies.

Results and Discussion

Preparation and Characterization of Amadori Rearrangement Product (ARP), 2—The Maillard reaction between fluoxetine and lactose to produce the ARP, **2**, is shown in Scheme 2. An authentic sample of **2** was obtained by reaction of lactose and fluoxetine HCl in *N,N*-dimethylacetamide and ethanol as solvent with triethylamine as the base. It was purified by extractions but was not crystallized.


Although the structure of **2** is shown as acyclic, it exists in solution as a mixture of pyranose and furanose forms both of which can be diastereomeric.²⁵ For this reason,

Reduced Adduct, 6

position ^b	fluoxetine, 1		ARP, 2		reduced adduct, 6 ^a	
	¹³ C	¹ H	¹³ C	¹ H	¹³ C	¹ H
1	44.99	2.99			53.88	3.29
2	34.01	2.31, 2.23		2.35, 2.28	51.30	3.26
3	76.38	5.74		5.58	31.88	2.36, 2.19
4	160.09	—	160.66	—	77.00	5.53
5, 9	116.28	7.08	116.20	7.06	160.10	—
6, 8	126.77	7.55	126.82	7.55	116.36	7.07
7	121.36	—	120.98	—	126.93	7.56
10	139.97	—	141.21	—	121.56	—
11, 15	125.94	7.42	126.19	7.46	139.87	—
12, 14	128.74	7.36	128.58	7.36	126.07	7.41
13	128.01	7.27	127.64	7.28	128.88	7.37
N-CH ₃	32.25	2.51			128.22	7.29
CF ₃	124.38	—	124.53	—	41.45	2.84
1'					39.21	2.78
2'					58.95	3.44, 3.04
3'					58.06	3.33, 3.15
4'					64.48	4.16
5'					71.41	3.58
6'					71.08	3.52
1''			4.28		75.32	3.39
2''					68.34	3.58
3''					61.06	3.54
4''					103.97	4.24
5''					70.65	3.33
6''					73.44	3.30
					70.01	3.65
					77.56	3.75
					62.20	3.66

complete characterization of **2** was not accomplished. Rather, sufficient mass spectral and NMR characterization was performed to be reasonably confident of the structure and this was supplemented with more complete characterization on the alcohol **6**, prepared by reduction of **2** with sodium borohydride. The NMR assignments can be found in Table 1. Several key elements were needed to confirm the structure of **6**. Specifically, the combination of proton–proton coupling (COSY) and proton–carbon long-range coupling (HMBC), along with basic proton and carbon chemical shift information, was used to show the following (refer to Table 1). First, the fluoxetine moiety in the molecule is intact. Second, the *N*-methyl protons of fluoxetine show coupling to the adjacent methylene C1 of fluoxetine, and more importantly to the methylene C1' of the lactose moiety, thereby establishing the site of union between the fluoxetine and the lactose. Finally, the galactose unit of the lactose has been retained. The anomeric carbon at 1'' maintains the downfield chemical shift of 103.9 ppm seen in lactose.²⁶ The HMBC experiment also shows coupling from the proton at 3.39 ppm of 4' to the 1'' carbon. Similarly, the 1'' proton at 4.24 ppm shows coupling to the 4' carbon at 75.3 ppm.

pH*	equiv KOH	percent per hour	
		ARP, 2	N-formyl-fluoxetine, 3
5.0	0	0.0014	0
7.0	0.07	0.084	0
8.0	0.50	0.31	0.040
8.4	1.05	0.16	0.22



Without addition of KOH, the apparent pH (pH^*) was 5.0 and the reaction was very slow. However, addition of only 0.07 equiv of KOH ($\text{pH}^* = 7.0$) increased the rate of appearance of **2** by a factor of 60. At higher pH values, the rate of formation of **2** increased further and the production of *N*-formylfluoxetine, **3**, was observed. Representative data from $\text{pH}^* = 8.0$ is shown in Figure 1. The peak assigned to the glycosylamine, **4**, eluted just before **2** and was assumed to be this compound based on the fact that it was the first visible product of the reaction, was quickly converted to **2**, and had a molecular weight of 633, as determined by LC/MS analysis. It is clear from this solution-phase study that the Maillard and Amadori reactions of fluoxetine HCl and lactose are viable processes and that they are readily catalyzed by base.

Formamides and acetamides are well-known products of the decomposition of Amadori rearrangement products, both for primary²⁷ and secondary amines.²⁸ Although both formylation and acetylation of fluoxetine have been observed in the studies reported here, the former has been observed throughout, often as the primary path of decomposition, whereas only small amounts of acetylation have been observed. Two paths to formamides in the Maillard

Table 3—Solid Phase Screening Experiments for Mixtures Heated at 98 °C for 24 h

lactose type	mixing mode	Mg stearate	% Impurities		
			total	ARP, 2	N-formyl- fluoxetine, 3
monohydrate	tumble	N	0.48	0.073	
		Y	0.46	0.16	0.023
	grind	N	0.48	0.089	
		Y	0.6	0.21	0.039
	wet grind	N	6.13	3.23	0.02
Y		17.3	8.56	0.4	
spray-dried	tumble	N	1.2	0.26	
		Y	0.92	0.4	0.036
	grind	N	1.48	0.45	0.02
		Y	1.44	0.41	0.12
	wet grind	N	22.8	5.1	0.078
Y		24.2	13	0.48	
anhydr gran	tumble	N	0.46	0.072	
	grind	N	0.5	0.079	
	wet grind	N	3.11	1.51	0.014
anhydr milled	tumble	N	0.44	0.079	
	grind	N	0.53	0.107	
	wet grind	N	2.06	0.86	0.011

reaction are generally considered: the oxidative cleavage of the glycosylamine (or a smaller fragment of it)³ or the acylation of free amine with a 1,2-dicarbonyl compound, especially glyoxal.²⁹ In the present case, addition of 0.1 equiv of glyoxal to a 0.1 M solution of fluoxetine HCl containing 0.5 equiv of KOH in aqueous ethanol at 60 °C did produce N-formylfluoxetine, 3, as well as a few other unidentified products. This is consistent with but does not prove that glyoxal is the precursor to N-formylfluoxetine in the solution or solid-phase experiments. Similar spiking experiments with formic acid or glyoxalic acid produced no new products.

Solid State Reactions, Monitored by HPLC—Having shown that the Maillard reaction of lactose and fluoxetine occurs in solution and that 2 and 3 are the expected products, attention turned to the more pharmaceutically relevant case of solid-phase reactions. The simplest experiment to identify such a drug–excipient interaction is visual observation of a heated mixture.³⁰ Such an approach was used over 30 years ago to warn formulation scientists of the browning of lactose formulations of drugs which contain primary and secondary amine functionality.³¹ Indeed, when lactose and fluoxetine HCl as a solid mixture were heated overnight at 100 °C, both browning and a characteristic malt-like odor were obvious. More recent studies designed to detect drug–excipient interactions generally rely upon the use of DSC³² or diffuse reflectance FT-IR.³³ We chose to use the gradient HPLC method to directly analyze products from solid-state reactions.

To identify the important factors which would influence the solid state Maillard reaction of lactose and fluoxetine HCl, a series of screening experiments with various lactose types, mixing methods, water content, and lubricant concentrations were performed. The experiments are described in the experimental section and the results are summarized in Table 3. Four commonly available types of lactose were screened. Three mixing modes were chosen to mimic typical drug product unit operations including blending, milling, and wet granulation. Experiments with lactose monohydrate were also repeated with magnesium stearate added since this lubricant was commonly found in the generic lactose formulations. The relatively high temperature of 98 °C was chosen for expediency; the results are for comparison within the experiment, not for prediction of overall rates of decomposition of drug mixtures




Figure 2—Lactose monohydrate and fluoxetine HCl at 85 °C.

under normal storage conditions. The gradient HPLC method was used to measure both the total amount of impurities as well as amounts of 2 and 3.

The level of total impurities by HPLC in the bulk fluoxetine HCl used for this experiment was 0.23%; the level did not increase by heating fluoxetine HCl by itself and no significant impurities were observed by heating a lactose control individually. Analysis of replicates indicates the relative error in the impurity measurements to be somewhat high, about 20%. However, the wide range of results still allows for several statistically valid conclusions. The Maillard reaction was observed in all experiments and its rate was slightly faster with spray-dried lactose than with lactose monohydrate. Many products were detected by HPLC analysis, most of which were early-eluting carbohydrate-containing materials based on LC/MS analysis. Water accelerates the process. The rate of ARP formation with anhydrous and monohydrate lactose forms were similar, but the anhydrous form was less sensitive to added water, possibly due to conversion to lactose monohydrate. The rate was not significantly different in blended mixtures versus ground mixtures. The addition of magnesium stearate catalyzed the formylation process. On the basis of the pH-dependent data generated in solution, this effect may be due to localized changes in pH rather than changes in physical mobility within the solids due to the lubricant. This set of experiments clearly indicated that the Maillard reaction of fluoxetine HCl and lactose were likely to occur, even in the solid phase, and that factors such as moisture content, type of lactose, and the presence of magnesium stearate could have an influence on the rates and the identities of subsequent decomposition products.

The analysis of several lactose-containing generic fluoxetine HCl products by X-ray powder diffraction (XRPD) indicated that only lactose monohydrate (or spray-dried lactose) was being used; therefore, additional work with the anhydrous forms was not pursued. X-ray analysis was also used to qualitatively verify that even after heating for several days at 100 °C and in mixtures with substantial amounts of impurities, crystalline lactose monohydrate remained; anhydrous lactose was not detected, although some amorphous material could have been present. To examine the rates of this drug–excipient interaction in more detail and at a lower temperature, a series of kinetic experiments was performed as described in the experimental section. These conditions were chosen to be more representative of stress stability conditions typically used during drug development. The impurity content of the starting fluoxetine HCl was 0.20%. Representative results for 85 °C are displayed in Figures 2–4, which use the same vertical scale for ease of comparison.




Figure 3—Spray-dried lactose and fluoxetine HCl at 85 °C.

It is evident that in this study, substantially more ARP (2) was formed with spray-dried lactose (Figure 3) than when lactose monohydrate was used (Figure 2), consistent with previous reports.¹³ In the former case, the total level of impurities exceeded 1% after just 1 day at 85 °C. Consistent with the screening study, the presence of magnesium stearate increased the amount of *N*-formylfluoxetine, 3; compare Figures 4 and 2. Control experiments with isolated fluoxetine HCl and lactose were performed; both are stable under the conditions studied.

Temperature-dependent analysis of the results was performed using the simplest model for the production of an unstable product (eq 1). Product X refers to decomposition products of 2, not any specific compound. The rates of formation of 2 and X were derived from eqs 2 and 3 in which T_r , the reference temperature, is 348 K. This modification was used to make the preexponential factor more independent of the activation energy, as suggested by Blau and co-workers in their description of Simusolv,³⁴ the simulation software in use. Only data for the concentration of 2 were used in the model since the identities of its degradation products, and thus their response factors, are largely unknown. Arrhenius parameters are summarized in Table 4.



$$\frac{d[2]}{dt} = k_1 \exp\left(\frac{E_1}{R}\left(\frac{1}{T_r} - \frac{1}{T}\right)\right)[1] - k_2 \exp\left(\frac{E_2}{R}\left(\frac{1}{T_r} - \frac{1}{T}\right)\right)[2] \quad (2)$$

$$\frac{d[X]}{dt} = k_2 \exp\left(\frac{E_2}{R}\left(\frac{1}{T_r} - \frac{1}{T}\right)\right)[2] \quad (3)$$

The last line in Table 4, an extrapolation to the time required for the sum of 2 and its degradants, X, to total 0.1% at 30 °C, according to eqs 2 and 3, is included as an indication of the possible real-time magnitude of this drug–excipient interaction. The prediction that this process should be observable at ambient temperature is confirmed by the detection of ARP, 2, in unstressed, unexpired lactose formulations; refer to Table 5. Figure 5 shows the experimental concentration of ARP, 2, versus time for the mixture of lactose monohydrate, fluoxetine HCl, and magnesium stearate at all three temperatures and the curves generated from eq 2 using the parameter estimates given in Table 4. Due to the competitive decomposition of 2, its concentration rises to a moderate level and remains fairly constant. That is, it is produced and consumed at approximately the same apparent rates. That it continues to be produced is




Figure 4—Lactose monohydrate, fluoxetine HCl, and magnesium stearate at 85 °C.

Table 4—Arrhenius Parameters for Fluoxetine HCl and Lactose Thermolysis Based on Eqs 1–3^a

parameter	monohydrate	spray-dried	monohydrate + Mg stearate
$k_1 \times 10^5$, 1/h	4.8(0.3)	6.9(0.9)	11.9(0.8)
$k_2 \times 10^2$, 1/h	2.4(0.2)	2.3(0.1)	4.0(0.3)
E_1 , kcal/mol	24.9(1.1)	34.9(1.3)	26.8(1.3)
E_2 , kcal/mol	13.4(1.8)	18.5(2.0)	16.6(1.5)
R^2 for model	0.97	0.96	0.98
months to 2 + X = 0.1% (30 °C)	5.9	34	3.5

^a The standard deviation is in parentheses.




Figure 5—Formation of ARP, 2, from solid-phase mixtures of lactose monohydrate, fluoxetine HCl, and magnesium stearate. Points are experimental; lines are from eq 2.

indicated by continued growth in other impurity peaks, including *N*-formylfluoxetine, 3.

Due to severe limitations on mobility, the kinetics of solid state systems, especially bimolecular ones, are not straightforward. Cohn utilized a function similar to the Arrhenius equation but which includes a parameter for the thickness of the reacting solid phases.³⁵ Carstensen has reviewed the problem as applied to the stability of solids and solid dosage forms and uses both the Arrhenius expression as well as Cohn's equation.³⁶ In the present study, the use of data from only the first few percent of the conversion minimizes the impact of these homogeneity issues, and the goodness of the fit to the model indicates that valid assumptions have been made.

The relevance of the above analysis to actual marketed generic fluoxetine HCl products was examined by replica-

Table 5—Stability of Fluoxetine HCl Products at 40 °C, 75% RH

product	impurity	% impurity by HPLC				
		initial	1 mo	3 mo	6 mo	9 mo
Prozac (starch)	total	0.17	0.19	0.21	0.23	0.23
	2					
	3		0.01	0.01	0.01	0.02
generic A (lactose)	total	0.43	0.47	0.60	0.90	1.10
	2	0.03	0.01	0.01	0.05	0.05
	3		0.02	0.03	0.13	0.22
generic Z (lactose)	total	0.30	0.35	0.45	0.63	0.74
	2		0.01	0.02	0.03	0.02
	3		0.01	0.04	0.08	0.13




Figure 6—Generic N, a fluoxetine HCl/lactose capsule at 85 °C.




Figure 7—Generic O, a fluoxetine HCl/lactose tablet at 85 °C.

tion of the stress stability study with a capsule (generic N) and a tablet (generic O). The results are shown in Figures 6 and 7, respectively. Both products displayed Maillard browning and produced 2, 3, and many other impurities. The results from the tablet (Figure 7) are comparable with decomposition profiles of the simple mixtures of lactose, drug, and magnesium stearate. However, the capsule was significantly less stable, showing formation of nearly 4% of 2 after 122 h at 85 °C, and a total impurity level of 13%. This implies the presence of additional catalysts in this capsule, the identities of which are unknown.

The third type of stability study on lactose formulations of fluoxetine HCl utilized the more standard accelerated conditions of 40 °C and 75% relative humidity used to support regulatory submissions. In this study the gradient HPLC assay was used to assess the stability of Prozac and two generic lactose-containing capsules, designated generic A and generic Z. The results from 9 months are given in

Table 5. Blanks indicate a level less than the detection limit of 0.01%.

Several points are of interest. First, the formulation with starch showed very limited impurity formation while the two formulations with lactose more than doubled in their total impurity content. Second, generic A (and other formulations examined) contain detectable amounts of 2 even before stressing, proving that the Maillard reaction occurs even at ambient temperature in unexpired products. Third, significant amounts of *N*-formylfluoxetine, 3, was produced by stressing both lactose formulations and its growth rate in generic A was faster than in generic Z, which may be due to the higher concentration of magnesium stearate in the former. Finally, although formation of 2 is proof of the Maillard reaction, its concentration may not rise to a very high level due to its conversion to other products, including 3. Thus, these formulations exhibited the same general behavior as noted in the solution phase experiments and the excipient interaction studies.

Solid-State Reactions Monitored by Headspace GC/MS—Although many of the products of the Maillard reaction are nonvolatile, such as the ARPs and melanoidins, many volatile products are produced as well. These have typically been identified by gas chromatography, especially by detection with a mass spectrometer. These studies frequently involve thermolysis of the ARP itself rather than the sugar–amine mixture. For example, Mills and Hodge studied the volatile products from pyrolysis of 1-deoxy-1-L-proline-D-fructose,³⁷ Hayase and Kato studied the glucose–butylamine system,²⁷ Birch et al. examined 1-amino-1-deoxyfructoses derived from alkylamines,³⁸ and Shigematsu et al. has identified volatile products from pyrolysis from several ARPs derived from glucose and amino acids.³⁹ Although a diverse array of products has been identified, some compounds or classes of compounds are almost always observed. These include carboxylic acids (especially formic and acetic acid), acyclic carbonyl compounds such as aldehydes and ketones, dicarbonyl compounds such as 2,3-pentanedione, furans such as furan itself but especially 2-furaldehyde and furfuryl alcohol, other oxygen-containing heterocycles such as pyranones and furanones and their dihydro counterparts, amides of the amines (especially formamides and acetamides), and, in cases where a primary amine was used, pyrroles and other nitrogen-containing heterocycles.

To provide the link between the drug–excipient interaction under study and the cited chemistry (which was done mainly with monosaccharides and simple amines or amino acids), we have examined the volatile products of the solid-state reaction of lactose monohydrate and fluoxetine HCl by GC/MS as reported in the experimental section. The data from six such experiments is summarized in Table 6. These include lactose–fluoxetine HCl with and without added magnesium stearate (5% relative to lactose), two generic capsule formulations, and two positive controls with dimethylamine HCl and piperidine HCl. The top part of the table contains products derived from the disaccharide while the lower portion contains products derived from the amine. Major products are indicated by +++ and minor ones by a single +; the quantities are thus relative within an experiment and between experiments but were not accurately determined.


Three “negative” controls, lactose alone, fluoxetine HCl alone, and a Prozac capsule (starch-based formulation) were also performed. Essentially no decomposition was observed; none of the compounds in Table 6 were produced in these control experiments.

All of the products derived from the sugar have been observed by previous workers in the Maillard–Amadori arena, thus clearly linking the present study to their

Table 6—Volatile Products from Pyrolysis (100 °C, 20 h) of Lactose and Secondary Amine Hydrochlorides

compound	GC/MS retention (min)	fluox HCl + lactose	fluox HCl + lactose + Mg stearate	generic A	generic Z	Me ₂ NH HCl + lactose + Mg St	piperidine HCl + lactose + Mg St
vinyl acetate ^a	3.1		+	+	+	+	+
acetic acid ^a	3.8	+	++	+++	+++	+++	+++
2,3-pentanedione ^a	5.47		+	+	+		
4-methyl-3-pentenal	6.70			+	+		
3-furaldehyde ^a	8.04					++	++
2-furaldehyde ^a	8.43			+		+	+
2-furfuryl alcohol ^a	9.12		+			+	+
3-furfuryl alcohol ^a	9.36		+		+	+	+
2-acetylfuran ^a	10.21			+		+	
isomaltol	11.79			+		+	+
maltol ^a	14.19	+	++	++		+	
2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one (5) ^a	14.79	+++		++		++	+
styrene ^a	10.12	+	+	+			
4-(trifluoromethyl)cresol ^a	13.45	+++	+++	+++	+++		
N-formylfluoxetine (3) ^a	29.34	+	+	+	+		
N,N-dimethylformamide ^a	7.09					++	
N,N-dimethylacetamide ^a	9.15					+	
N-formylpiperidine ^a	14.53						++
N-acetylpiperidine	15.74						+

^a Matched both the mass spectrum from a library and the retention time of authentic compound.



Scheme 3—Decomposition of ARP, 2.

findings. Of particular note is the widespread formation of 2-furaldehyde and other furans and 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one, 5; see Scheme 3. The identity of this compound was proven by comparison with authentic material, prepared according to a published method.⁴⁰ Kim and Baltes recently reported that many cyclic and acyclic Maillard products, including several listed in Table 6, can be derived from thermolysis of this pyranone.⁴¹ The possible presence of 1,2-dicarbonyl compounds (such as 2,3-pentanedione) in thermally stressed generic fluoxetine HCl products is of concern since some of them, including glyoxal and maltol, have been reported to be weak bacterial mutagens.⁴²

It is also noteworthy that many of the same products were produced from the reactions with the HCl salts of dimethylamine and piperidine as with fluoxetine HCl. For example, the formamides of all three amines were found as well as furaldehyde and maltol. This proves that fluoxetine is not unique or unusual in this regard; nearly all secondary amines whether cyclic or acyclic, should undergo similar reactions with lactose, in agreement with the bulk of the scientific literature.

The results of the studies on solution-phase experiments, solid-phase excipient interaction screening, stability studies on fluoxetine HCl and lactose and formulated products, and the analysis of products clearly prove that the Maillard reaction occurs in this system. Although the clinical significance of this drug–excipient interaction is unknown, the relevance of these findings to formulation scientists are more straightforward. Namely, the Maillard reaction of secondary amines and lactose should be considered when selecting formulation ingredients and when examining the stability of such products. However, in many cases, the formulation scientist will not know whether a specific nitrogen-containing drug will be compatible with reducing carbohydrates or not, usually due to significant structural

variations such as inclusion of the nitrogen within rings or the presence of functionality which would greatly diminish the nucleophilicity of the alkaloid drug. The present findings suggest a relatively simple experimental design to probe this question, namely, the use of the formamide derivative as a chemical marker for the Maillard reaction. In all systems studied here (and most in the literature in which their presence would have been detected) N-formyl compounds have been observed as a major product of the Maillard process. Therefore, simple reaction of an alkaloid drug with acetic formic anhydride should provide samples of N-formyl compound(s) which may or may not be isolated and purified, but which are usually stable and usually separable from the drug on chromatographic systems such as GC, HPLC, or electrophoresis. These derivatives will often be readily available and detectable and their formation in stressed samples of potential formulation mixtures will be a strong indication of the Maillard reaction. This chemical marker will be more accessible than Amadori rearrangement products since the latter are often unstable and are difficult to prepare, isolate, and characterize. The more traditional method of screening simply for color and odor is still possible; however, these sensory clues are not present in early stages of the Maillard process when impurity levels may exceed the level of 0.1%.¹⁸ An alternative screening program for the presence of Maillard-based drug–excipient interactions using GC/MS detection of volatile carbohydrate-derived compounds such as given in Table 6 could also be useful.

Acknowledgments

Technical advice from Fred M. Perry, Richard A. Berglund, Richard Frank, Douglas P. Kjell, Douglas E. Dorman, Bernard A. Olsen, and Kerry J. Hartauer is gratefully acknowledged. Additional assistance such as data manipulation and analytical support was provided by Willis V. Bell III, Sharon V. Snorek, Gary L. Thomas, Melinda R. Wilhelm, Patrick J. Jansen, and David G. Robbins. Elizabeth S. LaBell provided the sample of 3.

References and Notes

- (a) Maillard, L.-C. *C. R. Acad. Sci. Ser. 2*, **1912**, 154, 66. (b) Maillard, L.-C. *C. R. Acad. Sci. Ser. 2* **1912**, 155, 1554–6.

2. (a) Ellis, G. P. The Maillard Reaction. *Adv. Carbohydr. Chem.* **1959**, *14*, 63–134. (b) Hodge, J. E. Dehydrated Foods, Chemistry of Browning Reactions in Model Systems. *J. Agric. Food Chem.* **1953**, *1*, 928–43. (c) Yaylayan, V. A.; Huyghues-Despointes, A. *Crit. Rev. Food Sci. Nutr.* **1994**, *34*, 321–369.
3. (a) Ledl, F. Chemical Pathways of the Maillard Reaction. In *The Maillard Reaction in Food Processing, Human Nutrition and Physiology*; Finot, P. A., Aeschbacher, H. U., Hurrell, R. F., Liardon, R., Eds.; Birkhauser Verlag: Basel, 1990; pp 19–42. (b) Ledl, F.; Schleicher, E. New Aspects of the Maillard Reaction in Foods and in the Human Body. *Angew. Chem., Int. Ed. Engl.* **1990**, *29*, 565–94.
4. Paulsen, H.; Pflughaupt, K.-W. Glycosylamines. In *The Carbohydrates, Chemistry and Biochemistry*, Horton, D., Pigman, W., Eds.; Academic Press: New York, 1980; Vol. 1b, pp 881–927.
5. Hodge, J. E. The Amadori Rearrangement. *Adv. Carbohydr. Chem.* **1955**, *10*, 169–205.
6. Ledl, F.; Fritsch, G.; Hiebl, J.; Pachmayer, O.; Severin, T. Degradation of Maillard Products. In *Amino-Carbonyl Reactions in Food and Biological Systems*; Fujimaki, M., Namiki, M., Kato, H., Eds.; Elsevier: Amsterdam, 1986; pp 173–82.
7. Pischetsrieder, M.; Severin, T. The Maillard Reaction of Disaccharides. In *Maillard Reactions in Chemistry, Food, and Health*; Labuza, T. P., Reineccius, G. A., Monnier, V., O'Brien, J., Baynes, J., Eds.; Spec. Pub. 151; Royal Soc. Chem.: London, 1994; pp 37–42.
8. Van Boekel, M. A. J. S.; Berg, H. E. Kinetics of the Early Maillard Reaction During Heating of Milk. In *Maillard Reactions in Chemistry, Food, and Health*; Labuza, T. P., Reineccius, G. A., Monnier, V., O'Brien, J., Baynes, J., Eds.; Spec. Pub. 151; Royal Soc. Chem.: London, 1994; pp 170–5.
9. Hodge, J. E.; Rist, C. E. The Amadori Rearrangement under New Conditions and its Significance for Nonenzymatic Browning Reactions. *J. Am. Chem. Soc.* **1953**, *75*, 316–322. See also refs 2–4.
10. Colaco, C. A. L. S.; Collett, M.; Roser, B. J. Pharmaceutical Formulation Instability and the Maillard Reaction. *Chem. Oggi* **1996**, *14*, 32–7.
11. Kumar, V.; Banker, G. S. Maillard Reaction and Drug Stability. In *Maillard Reactions in Chemistry, Food, and Health*; Labuza, T. P., Reineccius, G. A., Monnier, V., O'Brien, J., Baynes, J., Eds.; Spec. Pub. 151; Royal Soc. Chem.: London, 1994; pp 20–27.
12. Wong, D. T.; Bymaster, F. P.; Engleman, E. A. Prozac (Fluoxetine, Lilly 110140), The First Selective Serotonin Uptake Inhibitor and an Antidepressant Drug: Twenty Years Since its First Publication. *Life Sci.* **1995**, *57*, 411–41.
13. Goodhart, F. W. Lactose, In *Handbook of Pharmaceutical Excipients*, 2nd ed.; Wade, A., Weller, P. J., Eds.; American Pharmaceutical Association: Washington DC, 1994; pp 252–7.
14. Wolfrom, M. L.; Cavalieri, L. F.; Cavalieri, D. K. Chemical Interactions of Amino Compounds and Sugars. II. Methylation Experiments. *J. Am. Chem. Soc.* **1947**, *69*, 2411–3.
15. Duvall, R. N.; Koshy, K. T.; Pyles, J. W. Comparison of Reactivity of Amphetamine, Methamphetamine, and Dimethylamphetamine with Lactose and Related Compounds. *J. Pharm. Sci.* **1965**, *54*, 607–611.
16. Simon, H.; Kraus, A. *Fortschr. Chem. Forsch.* **1970**, *14*, 430–70.
17. Simon, H.; Palm, D. *Chem. Ber.* **1965**, *98*, 433–45.
18. (a) Labuza, T. P. Interpreting the Complexity of the Kinetics of the Maillard Reaction. In *Maillard Reactions in Chemistry, Food, and Health*; Labuza, T. P., Reineccius, G. A., Monnier, V., O'Brien, J., Baynes, J., Eds.; Spec. Pub. 151; Royal Soc. Chem.: London, 1994; pp 176–181. (b) Labuza, T. P.; Baister, W. M. The Kinetics of Nonenzymatic Browning. In *Physical Chemistry of Foods*; Schwartzberg, H. G., Hartel, R. W., Eds.; Marcel Dekker: New York, 1992; pp 595–649.
19. Pischetsrieder, M.; Severin, T. Advanced Maillard Products of Disaccharides: Analysis and Relation to Reaction Conditions. In *Chemical Markers for Processed and Stored Foods*; Lee, T.-C., Kim, H.-J., Eds.; ACS Symposium Series 631; Am. Chem. Soc.: Washington, DC, 1996; pp 14–23. See also refs 1–10.
20. Wirth, D. D.; Olsen, B. A.; Hallenbeck, D. K.; Lake, M. E.; Gregg, S. M.; Perry, F. M. Screening Methods for Impurities in Multi-sourced Fluoxetine Hydrochloride Drug Substances and Formulations. *Chromatographia* **1997**, *46*, 511–23.
21. US Pharmacopeia **1997**, 23, Seventh Supplement, 3890–2.
22. Aue, W. P.; Bartholdi, E.; Ernst, R. R. Two-Dimensional Spectroscopy. Application to Nuclear Magnetic Resonance. *J. Chem. Phys.* **1976**, *64*, 2229–46.
23. Bax, A.; Subramanian, S. Sensitivity-Enhanced Two-Dimensional Heteronuclear Shift Correlation NMR Spectroscopy. *J. Magn. Reson.* **1986**, *67*, 565–9.
24. Bax, A.; Summers, M. F. Proton and Carbon-13 Assignments from Sensitivity-Enhanced Detection of Heteronuclear Multiple-Bond Connectivity by 2D Multiple Quantum NMR. *J. Am. Chem. Soc.* **1986**, *108*, 2093–4.
25. Tjan, S. B.; van den Ouweland, G. A. M. PMR Investigation into the Structure of some N-Substituted 1-Amino-1-deoxy-D-fructoses (Amadori Rearrangement Products). *Tetrahedron* **1974**, *30*, 2891–7.
26. (a) Bailey, K.; Butterfield, A. G. Structure of Condensation Products between Isonicotinylhydrazine and Reducing Sugars by ¹³C NMR Spectroscopy. *Can. J. Chem.* **1981**, *59*, 641–6. (b) Platzer, N.; Davoust, D.; Lhermitte, M.; Bauvy, C.; Meyer, D. M.; Derappe, C. Structural Analysis of Five Lactose-Containing Oligosaccharides by Improved High-Resolution, Two-Dimensional Proton NMR Spectroscopy. *Carbohydr. Res.* **1989**, *191*, 191–207.
27. Hayase, F.; Kato, H. Low-Molecular Maillard Reaction Products and Their Formation Mechanisms. In *Amino-Carbonyl Reactions in Food and Biological Systems*; Fujimaki, M., Namiki, M., Kato, H., Eds.; Elsevier: Amsterdam, 1986; pp 39–48.
28. Mills, F. D.; Baker, B. G.; Hodge, J. E. Thermal Degradation of 1-Deoxy-1-piperidino-D-Fructose. *Carbohydr. Res.* **1970**, *15*, 205–13.
29. Hayase, F.; Kim, S. B.; Kato, H. Maillard Reaction Products Formed from D-Glucose and Glycine and the Formation Mechanisms of Amides as Major Components. *Agric. Biol. Chem.* **1986**, *49*, 2337–41.
30. Castello, R. A.; Mattock, A. M. Discoloration of Tablets Containing Amines and Lactose. *J. Pharm. Sci.* **1962**, *51*, 106–8.
31. Hammouda, V.; Salakawy, S. A. Lactose-induced Discoloration of Amino Drugs in Solid Dosage Form. *Pharmazie* **1971**, *26*, 181.
32. (a) van Dooren, A. A. Design for Drug-Excipient Interaction Studies. *Drug Dev. Ind. Pharm.* **1983**, *9*, 43–55. (b) Chrzanoski, F. A.; Uliissi, L. A.; Fegely, B. J.; Newman, A. C. Preformulation Excipient Compatibility Testing. Application of a Differential Scanning Calorimetric Method versus a Wet Granulation Simulating, Isothermal Stress Methodol. *Drug Dev. Ind. Pharm.* **1986**, *12*, 783–800.
33. Hartauer, K. J.; Guillory, J. K. A Comparison of Diffuse Reflectance FT-IR Spectroscopy and DSC in the Characterization of a Drug-Excipient Interaction. *Drug Dev. Ind. Pharm.* **1991**, *17*, 617–30.
34. Blau, G. E.; Kuenker, K. E.; Agin, G. L.; Steiner, E. C. Chemical Reactor Design and Analysis with Simusolv, presented at the 7th International Symposium on Large Chemical Plants, October 6–7, 1988, Brugge, Belgium. Simusolv is a trademark of The Dow Chemical Company.
35. Cohn, G. Reactions in the Solid State. *Chem. Rev. (Washington, D.C.)* **1948**, *42*, 527–73.
36. Carstensen, J. T. Stability of Solids and Solid Dosage Forms. *J. Pharm. Sci.* **1974**, *63*, 1–14.
37. Mills, F. D.; Hodge, J. E. Amadori Compounds: Vacuum Thermolysis of 1-Deoxy-1-L-Proline-D-Fructose. *Carbohydr. Res.* **1976**, *51*, 9–21.
38. Birch, E. J.; Lelievre, J.; Richards, E. L. Influence of the amine moiety on the thermal degradation of N-substituted 1-amino-1-deoxyfructoses. *Carbohydr. Res.* **1984**, *128*, 351–5.
39. Shigematsu, H.; Shibata, S.; Kurata, T.; Kato, H.; Fujimaki, M. Thermal Degradation Products of Several Amadori Compounds. *Agric. Biol. Chem.* **1977**, *41*, 2377–85.
40. Van Den Ouweland, G. A. M.; Peer, H. G. Synthesis of 3,5-Dihydroxy-2-methyl-5,6-dihydropyran-4-one from Aldoheoses and Secondary Amine Salts. *Rec. Trav. Chim. Pays-Bas* **1970**, *89*, 750–4.
41. Kim, M.-O.; Baltes, W. On the Role of 2,3-Dihydro-3,5-dihydroxy-6-methyl-4(H)-pyran-4-one in the Maillard Reaction. *J. Agric. Food Chem.* **1996**, *44*, 282–9.
42. Bjeldanes, L. F.; Chew, H. Mutagenicity of 1,2-Dicarbonyl Compounds: Maltol, Kojic Acid, Diacetyl and Related Substances. *Mutation Res.* **1979**, *67*, 367–71.

JS9702067